检索了罗氏公司血管内皮生长因子(vascular endothelial growth factor,VEGF)抗体相关专利申请情况,分析了贝伐珠单抗和兰尼单抗的技术研发路线、罗氏公司VEGF抗体相关在华专利布局情况,对其未来技术研发趋势和方向进行了预测。
This paper analyzes the technical development route of bevacizumab and ranibizumab based on the vascular endothelial growth factor (VEGF) antibody related patent applications of Roche. The layout in China of the VEGF related patents of Roche is also analyzed. Based on the above analyses, the future trends and directions of the technical research and development of VEGF antibody technology are predicted.
[1] Ferrara N, Hillan K J, Gerber H P, et al.Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer[J].Nature Re-views Drug Discovery, 2004, 3(5): 391-400.
[2] Steinbrook R.The price of sight-ranibizumab, bevacizumab, and the treatment of macular degeneration[J].New England Journal of Medi-cine, 2006, 355(14): 1409-1412.
[3] 吴炜霖, 仲人前.人源化抗体的演进发展及应用现状[J].现代免疫学.2009, 29(4):337-340.Wu Weilin, Zhong Renqian.Development and application of humanized antibody[J].Current Immunology.2009, 29(4):337-340.
[4] Aiello L P, Avery R L, Arrigg P G, et al.Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other reti-nal disorders[J].New England Journal of Medicine, 1994, 331(22): 1480-1487.
